Summary & Overview
HCPCS Level II J9268: Injection, Pentostatin 10 mg
HCPCS Level II code J9268 denotes a 10 mg injectable dose of pentostatin, an antineoplastic agent used in oncology care. Nationally, accurate coding for single-agent chemotherapy products like pentostatin matters for claims processing, site-of-service classification, and drug cost reporting. This code is relevant to a range of payers and care settings where parenteral chemotherapy is delivered.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9268 represents clinically and administratively, along with typical sites of service and the service type for which it is used. The publication provides benchmarks and policy context relevant to billing injectable oncology drugs, highlights common billing modifiers and payer considerations, and summarizes clinical context for pentostatin use. Where specific input fields were not provided, the text notes that data are not available in the input.
Billing Code Overview
HCPCS Level II code J9268 represents the administration of pentostatin delivered by injection in a 10 mg unit. This code denotes the medication product itself rather than the professional service of administering the drug. The service type associated with this code is injectable chemotherapeutic/antineoplastic drug supply. The typical site of service for billing this code is an outpatient infusion center, hospital outpatient department, or clinic where parenteral oncology treatments are provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old male with relapsed/refractory T-cell prolymphocytic leukemia (or other hematologic malignancy for which pentostatin is indicated) presents to the outpatient oncology infusion center for administration of J9268 (Injection, pentostatin, 10 mg). The oncology nurse performs pre-infusion assessment including vital signs, review of recent laboratory tests (complete blood count, renal and hepatic function), oral mucosa inspection, and confirmation of informed consent and medication order. The pharmacist verifies dose calculation based on body surface area or weight per the prescribing oncologist, prepares the appropriate number of 10 mg vials, and documents lot numbers and expiration. The infusion is typically given intravenously over the recommended infusion time with appropriate infusion pump and IV access; supportive orders (antiemetics, hydration) are administered as indicated. During and after infusion, the patient is monitored for infusion-related reactions, bone marrow suppression, and infectious complications. Documentation includes medication administration record with J9268, any applicable modifier (for example JW for discarded drug, or QX/QY for infusion services with professional/technical components where applicable), pre- and post-infusion assessments, and billing charge capture for drug units and associated infusion services. Typical sites of service include outpatient hospital infusion centers, physician office infusion suites, and ambulatory infusion centers.
Coding Specifications
| Modifier | Description |
|---|